Adntro Relies on Lanzadera to Boost the Commercialization of its Genetic Screening Kit

Adntro steps on the accelerator for the commercialization of its tests. The Balearic startup selected by Lanzadera, the accelerator promoted by the president of Mercadona, Juan Roig, has opened financing round with the aim of expanding the market of its genetic detection kit. The amount of this round has not been disclosed.

Since October 2020, the company has been marketing a saliva test capable of detecting the genetic variables of each user. The sequencing analyzes different parameters of their health status, such as pharmacogenetics, possible diseases, and nutritional intolerances.

The round already has the support of several partners and is expected to close by the end of the first quarter of 2022, as confirmed by the company’s CEO, Guillermo Perez-Solero, to PlantaDoce. The shuttle support will crystallize in the company through three phases. The first, aimed at financing, has not yet been launched. The second is focused on training, while the last is based on providing the various selected start-ups with an entrepreneurial ecosystem to develop their businesses.

Discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech. Read more about Adntro’s new genetic detection kit and stay on top of the market with our companion app.

Adntro already markets its tests in sixty countries on five continents

Despite its desire to expand markets, Adntro already markets its tests in sixty countries on five continents, although the company’s priority markets will continue to be Spain and Latin America. The kits are manufactured in Spain, but the sequencing is carried out in Denmark. The price of each unit ranges from $112 (€99) to $141.5 (€125), depending on the level of analysis chosen.

From the end of 2021, Adntro has also committed to diversifying its business, entering the hospital business. The company has launched a pilot program in several private hospitals, which aims to implement its software tool oriented to the analysis of genetic data and detection of genetic variants at risk.

This big data solution is intended to act as a data management support for healthcare centers. Currently, Adntro is already working with different private clinics in Spain and Argentina.

Adntro is already working with different private clinics in Spain and Argentina

For its part, since its founding in 2013, Lanzadera has promoted nearly 900 companies and has provided more than twenty million euros in loans. Depending on their needs, the selected companies can receive from grants of one thousand euros to financing worth half a million euros.

Last year, Lanzadera incorporated Genetracer Biotech, AcceXible, Genotipia, Iakan and Rehametrics. This accelerator selected for the May call seventy start-ups that develop innovative solutions in various sectors. HumanITcare has also collaborated with the project.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.